Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -4 of 4
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
10/14/2008
 
First Published:
6/25/2005
1.
Phase I/II Randomized Study of Adjuvant Vaccine Therapy Comprising Multi-Epitope Melanoma Peptides in Combination With Either Multi-Epitope Melanoma Helper Peptides or Tetanus Toxoid Helper Peptide Emulsified in Montanide ISA-51 With Versus Without Cyclophosphamide in Patients With Resected Stage IIB-IV Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
18 and over
NCI
UVACC-HIC-11491
Mel 44, UVACC-34104, UVACC-MEL-44, UVACC-GCRC-CLS013, UVACC-HITC-02620, MDA-2005-0070, NCT00118274
Last Modified:
10/14/2008
 
First Published:
8/24/2006
2.
Phase II Study of Vaccine Therapy Comprising Synthetic Ovarian Cancer-Associated Peptides Administered With a Synthetic Tetanus Toxoid Helper Peptide Emulsified in Montanide ISA-51 Before or After Paclitaxel and Carboplatin in Patients With Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Undergoing Optimal Cytoreductive Surgery
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Biomarker/Laboratory analysis, Treatment
Closed
18 and over
NCI
UVACC-OVA-2
OVA-2, UVACC-HIC-10134, UVACC-PRC-236-02, NCT00373217
Last Modified:
2/6/2008
 
First Published:
8/24/2004
3.
Phase I Study of Adjuvant Vaccine Comprising Ovarian Cancer Synthetic Peptides, Tetanus Toxoid Helper Peptide, and Sargramostim (GM-CSF) Emulsified in Montanide ISA-51 in Patients With Previously Treated Ovarian Epithelial or Primary Peritoneal Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
NCI
UVACC-OVA3
UVACC-33204, UVACC-HIC-11276, NCT00091273
Last Modified:
7/10/2006
 
First Published:
6/25/2005
4.
Phase I Randomized Study of Adjuvant Transdermal Vaccine Therapy Comprising Multi-Epitope Melanoma Peptides, Tetanus Toxoid Helper Peptide, and Sargramostim (GM-CSF) in Combination With Either Montanide ISA-51 or Dimethyl Sulfoxide With or Without Imiquimod in Patients With Resected Stage II-IV Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
12 and over
NCI
UVACC-MEL-45
UVACC-HIC-11490, UVACC-34204, NCT00118313
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute